Home › NCT06655324
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants.
Who can join
Ages 12 to 30 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health before randomization. * Has a body mass index between 18 and 38 kg/m\^2, inclusive, for adults 18-30; has a body mass index between 15 and 38 kg/m\^2, inclusive, for adolescents 12-17. Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a confirmed or suspected case of infectious mononucleosis within 12 months prior to enrollment. * Has any immunosuppressive medical condition or receive any immunosuppressive therapy.
About the study
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
What is being tested
- V350A (biological)
- V350B (biological)
- Placebo (biological)
Sponsor: Merck Sharp & Dohme LLC · Participants: 250 · Started: Dec 5, 2024
Contact the study team
- Toll Free Number · Phone: 1-888-577-8839
Official record on ClinicalTrials.gov — NCT06655324
Locations in the U.S.
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.